148.61

1.21% -1.82

Gilead Sciences Inc (GILD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$150.43

Aprire:

$151.16

Volume 24 ore:

796.95K

Relative Volume:

0.16

Capitalizzazione di mercato:

$184.27B

Reddito:

$29.79B

Utile/perdita netta:

$9.22B

Rapporto P/E:

20.22

EPS:

7.3494

Flusso di cassa netto:

$10.23B

1 W Prestazione:

+3.04%

1M Prestazione:

+3.40%

6M Prestazione:

+6.89%

1 anno Prestazione:

+25.72%

Intervallo 1D:

$148.24

$151.16

Intervallo di 1 settimana:

$144.65

$152.26

Portata 52W:

$114.02

$157.29

Gilead Sciences Inc Stock (GILD) Company Profile

Nome

Gilead Sciences Inc

Settore

Healthcare (1051)

Industria

Drug Manufacturers - General (21)

Telefono

(650) 574-3000

Indirizzo

333 LAKESIDE DR, FOSTER CITY, CA

Dipendente

17,000

Cinguettio

@GileadSciences

Prossima data di guadagno

2026-10-29

Ultimi documenti SEC

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, MRK, NVS

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GILD Gilead Sciences Inc	148.61	184.27B	29.79B	9.22B	10.23B	7.3494
LLY Lilly Eli Co	1,174.20	1.05T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	249.24	600.64B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	277.19	489.82B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	143.59	354.26B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	143.20	272.18B	54.66B	13.58B	16.05B	7.0171

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-07-21	Downgrade	Leerink Partners	Outperform → Market Perform
2026-07-06	Aggiornamento	HSBC Securities	Hold → Buy
2026-05-20	Aggiornamento	Maxim Group	Hold → Buy
2026-03-10	Iniziato	Jefferies	Buy
2026-02-20	Iniziato	Barclays	Equal Weight
2026-02-11	Reiterato	Needham	Buy
2026-01-07	Ripresa	UBS	Buy
2025-11-24	Ripresa	Truist	Buy
2025-11-13	Iniziato	Scotiabank	Sector Outperform
2025-08-19	Aggiornamento	Daiwa Securities	Neutral → Outperform
2025-08-08	Aggiornamento	Truist	Hold → Buy
2025-07-25	Aggiornamento	Needham	Hold → Buy
2025-04-22	Ripresa	Cantor Fitzgerald	Overweight
2025-03-04	Reiterato	Oppenheimer	Outperform
2025-02-18	Aggiornamento	Deutsche Bank	Hold → Buy
2025-02-13	Aggiornamento	DZ Bank	Hold → Buy
2025-01-10	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Ripresa	BofA Securities	Buy
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-11-14	Iniziato	Citigroup	Buy
2024-11-08	Downgrade	Maxim Group	Buy → Hold
2024-10-21	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-10-17	Iniziato	Bernstein	Outperform
2024-10-07	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2024-07-08	Aggiornamento	Raymond James	Mkt Perform → Outperform
2024-05-01	Reiterato	Maxim Group	Buy
2024-04-24	Aggiornamento	HSBC Securities	Reduce → Hold
2024-02-22	Downgrade	Truist	Buy → Hold
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-09-08	Aggiornamento	BofA Securities	Neutral → Buy
2023-09-06	Iniziato	HSBC Securities	Reduce
2023-07-24	Reiterato	Barclays	Equal Weight
2023-05-16	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Ripresa	Piper Sandler	Overweight
2023-01-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Ripresa	BofA Securities	Neutral
2022-12-09	Downgrade	DZ Bank	Buy → Hold
2022-10-31	Aggiornamento	Barclays	Underweight → Equal Weight
2022-10-28	Reiterato	BMO Capital Markets	Market Perform
2022-10-28	Reiterato	Cowen	Outperform
2022-10-28	Reiterato	JP Morgan	Overweight
2022-10-28	Reiterato	Jefferies	Buy
2022-10-28	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-28	Reiterato	RBC Capital Mkts	Outperform
2022-10-28	Aggiornamento	Truist	Hold → Buy
2022-10-28	Reiterato	Wells Fargo	Equal Weight
2022-10-04	Aggiornamento	JP Morgan	Neutral → Overweight
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-05-23	Iniziato	SVB Leerink	Mkt Perform
2022-02-28	Downgrade	BMO Capital Markets	Outperform → Market Perform
2022-02-02	Reiterato	BMO Capital Markets	Outperform
2022-02-02	Reiterato	BofA Securities	Neutral
2022-02-02	Reiterato	RBC Capital Mkts	Outperform
2022-02-02	Reiterato	Truist	Hold
2022-02-02	Reiterato	Wells Fargo	Equal Weight
2022-01-28	Aggiornamento	Argus	Hold → Buy
2022-01-06	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Ripresa	Wells Fargo	Equal Weight
2021-12-06	Iniziato	Goldman	Neutral
2021-11-19	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Ripresa	Piper Sandler	Neutral
2021-10-20	Ripresa	Cowen	Outperform
2021-07-30	Reiterato	BMO Capital Markets	Market Perform
2021-07-30	Reiterato	RBC Capital Mkts	Outperform
2021-04-01	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-03-30	Aggiornamento	Redburn	Neutral → Buy
2021-01-19	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	Aggiornamento	Guggenheim	Neutral → Buy
2020-11-03	Ripresa	Morgan Stanley	Equal-Weight
2020-10-28	Iniziato	UBS	Neutral
2020-09-30	Ripresa	Jefferies	Buy
2020-09-15	Aggiornamento	Maxim Group	Hold → Buy
2020-07-31	Reiterato	Credit Suisse	Neutral
2020-07-31	Reiterato	Morgan Stanley	Equal-Weight
2020-07-31	Reiterato	Piper Sandler	Overweight
2020-07-31	Reiterato	RBC Capital Mkts	Outperform
2020-07-31	Reiterato	SunTrust	Hold
2020-07-31	Reiterato	Wells Fargo	Equal Weight
2020-07-20	Aggiornamento	Credit Suisse	Underperform → Neutral
2020-06-03	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2020-05-26	Aggiornamento	SunTrust	Sell → Hold
2020-05-01	Downgrade	JP Morgan	Overweight → Neutral
2020-05-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-05-01	Downgrade	SunTrust	Hold → Sell
2020-04-27	Downgrade	UBS	Buy → Neutral
2020-04-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-04-20	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-04-17	Downgrade	CFRA	Hold → Sell

Mostra tutto

Gilead Sciences Inc Borsa (GILD) Ultime notizie

05:20 AM

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

05:20 AM

Oct 12, 2026

Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says - Yahoo Finance

Oct 12, 2026

Can Gilead (GILD) Stock Continue Rising in 2027? - Yahoo Finance

Oct 12, 2026

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research

Oct 12, 2026

BofA raises Gilead Sciences stock price target on growth outlook By Investing.com - Investing.com India

Oct 12, 2026

RBC raised target for Gilead Sciences stock to USD 126.00 - ad-hoc-news.de

Oct 12, 2026

Oct 11, 2026

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool

Oct 11, 2026

Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive? - Yahoo Finance

Oct 11, 2026

Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales? - Yahoo Finance

Oct 11, 2026

Oct 09, 2026

Gilead Sciences (GILD) Laps the Stock Market: Here's Why - Zacks Investment Research

Oct 09, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 09, 2026

RBC raises target for Gilead Sciences stock to USD 126.00 - AD HOC NEWS

Oct 09, 2026

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research

Oct 09, 2026

Oct 08, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo! Finance Canada

Oct 08, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo Finance

Oct 08, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo Finance

Oct 08, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat

Oct 08, 2026

Cantor Fitzgerald Reaffirms Overweight Rating for Gilead Sciences (NASDAQ:GILD) - MarketBeat

Oct 08, 2026

Oct 07, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - TradingView

Oct 07, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 07, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat

Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Gets Price Target Boost from JPMorgan Chase & Co. - MarketBeat

Oct 07, 2026

U.S. Stocks Slip Ahead of Fed Minutes; Gilead Sciences (GILD) Ga - GuruFocus

Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Target Cut by Morgan Stanley - MarketBeat

Oct 07, 2026

Gilead Sciences Is Maintained at Overweight by Morgan Stanley - Moomoo

Oct 07, 2026

Gilead Sciences stock gains 2.57 percent after AI agreement expands - AD HOC NEWS

Oct 07, 2026

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) - Benzinga

Oct 07, 2026

JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160 - marketscreener.com

Oct 07, 2026

Gilead Sciences signs five-year DevOps agreement with Cognizant - Pharmaceutical Technology

Oct 07, 2026

Gilead Sciences signs five-year DevOps agreement with Cognizant - Yahoo Finance

Oct 07, 2026

Oct 06, 2026

Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences - BioSpace

Oct 06, 2026

Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences - PR Newswire

Oct 06, 2026

Drugmaker Gilead gets AI support for selected tech programs under a five-year extension - Stock Titan

Oct 06, 2026

Oct 05, 2026

12,110 Gilead Sciences, Inc. $GILD Shares Sold by CapWealth Advisors LLC - MarketBeat

Oct 05, 2026

Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support - ChartMill

Oct 05, 2026

Oct 02, 2026

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP - The Motley Fool

Oct 02, 2026

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Zacks Investment Research

Oct 02, 2026

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance

Oct 02, 2026

Under a prearranged trading plan, Gilead Sciences (GILD) CEO sells 15,000 shares. - Stock Titan

Oct 02, 2026

Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch

Oct 02, 2026

Oct 01, 2026

Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 01, 2026

More Upside Awaits for Gilead Sciences Stock. Stay Invested. - Barron's

Oct 01, 2026